Rasagiline Versus Entacapone in PD (AAN 2004)

Subject: Rasagiline Versus Entacapone in PD (AAN 2004)

Date: 5/28/2004

E-MOVE reports from the American Academy of Neurology, San Francisco April 25-30, 2004. Page (A), session (S) and poster (P) numbers are from Neurology 2004;62(7), Suppl 5

1. A comparative randomised study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson’s disease (PD) patients with motor fluctuations (the LARGO study)
O Rascol, DJ Brooks, A Melamed, W Oertel, W Poewe, F Stocchi, E Tolosa, LARGO Study Group
S38.004, A346

Rasagiline and entacapone are equally effective for reduction of off time in PD, according to this study.

Six hundred eighty-seven PD patients with motor fluctuations were randomized to receive placebo, rasagiline (1.0 mg once daily), or entacapone (200 mg with each levodopa dose) as adjunctive therapy. Mean daily off time at baseline was 5.6 hours, which decreased by 1.2 hours for both rasagiline and entacapone (p<0.0001 vs. placebo reduction of 0.4 hours). Mean daily dose of levodopa was reduced by 24 mg on rasagiline and 19 mg on entacapone. Frequency of adverse reactions was similar among all groups, and neither active treatment increased dyskinesia.

2. Rasagiline treatment can improve freezing of gait in advanced Parkinson’s disease: A prospective, randomized, double-blind, placebo- and entacapone-controlled study
N Giladi, O Rascol, DJ Brooks, E Melamed, WH Oertel, W Poewe, F Stocchi, E Tolosa, LARGO Study Group
P04.137, A329-330

Four hundred fifty-four patients with some degree of freezing of gait (FoG) were randomized to receive rasagiline, entacapone, or placebo. Baseline mean FoG score was 12 (24 maximum). Placebo reduced FoG by 0.5 points, versus 1.2 points for rasagiline (p=0.045), and 1.1 points for entacapone (p=0.066). No strong correlation was found for FoG reduction and off time reduction.

E-MOVE Editor: Richard Robinson, NASW, WE MOVE

Related CME Activities - Valid for AMA PRA Category 1 Credits(s)™